294 related articles for article (PubMed ID: 24813620)
1. Outcomes in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with isolated deletion 5q treated with lenalidomide: a subset analysis from the MDS-004 study.
Giagounidis A; Mufti GJ; Mittelman M; Sanz G; Platzbecker U; Muus P; Selleslag D; Beyne-Rauzy O; te Boekhorst P; del Cañizo C; Guerci-Bresler A; Nilsson L; Lübbert M; Quesnel B; Ganser A; Bowen D; Schlegelberger B; Göhring G; Fu T; Benettaib B; Hellström-Lindberg E; Fenaux P
Eur J Haematol; 2014 Nov; 93(5):429-38. PubMed ID: 24813620
[TBL] [Abstract][Full Text] [Related]
2. Lenalidomide does not increase AML progression risk in RBC transfusion-dependent patients with Low- or Intermediate-1-risk MDS with del(5q): a comparative analysis.
Kuendgen A; Lauseker M; List AF; Fenaux P; Giagounidis AA; Brandenburg NA; Backstrom J; Glasmacher A; Hasford J; Germing U;
Leukemia; 2013 Apr; 27(5):1072-9. PubMed ID: 23257782
[TBL] [Abstract][Full Text] [Related]
3. A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del5q.
Fenaux P; Giagounidis A; Selleslag D; Beyne-Rauzy O; Mufti G; Mittelman M; Muus P; Te Boekhorst P; Sanz G; Del Cañizo C; Guerci-Bresler A; Nilsson L; Platzbecker U; Lübbert M; Quesnel B; Cazzola M; Ganser A; Bowen D; Schlegelberger B; Aul C; Knight R; Francis J; Fu T; Hellström-Lindberg E;
Blood; 2011 Oct; 118(14):3765-76. PubMed ID: 21753188
[TBL] [Abstract][Full Text] [Related]
4. Lenalidomide: a review of its use in patients with transfusion-dependent anaemia due to low- or intermediate-1-risk myelodysplastic syndrome associated with 5q chromosome deletion.
Syed YY; Scott LJ
Drugs; 2013 Jul; 73(11):1183-96. PubMed ID: 23824699
[TBL] [Abstract][Full Text] [Related]
5. Lenalidomide in patients with red blood cell transfusion-dependent myelodysplastic syndrome and del(5q): a single-centre "real-world" experience.
Cerqui E; Pelizzari A; Schieppati F; Borlenghi E; Pagani C; Bellotti D; Lamorgese C; Boiocchi L; Sottini A; Imberti L; Rossi G
Leuk Lymphoma; 2015; 56(11):3129-34. PubMed ID: 25811676
[TBL] [Abstract][Full Text] [Related]
6. Patients with del(5q) MDS who fail to achieve sustained erythroid or cytogenetic remission after treatment with lenalidomide have an increased risk for clonal evolution and AML progression.
Göhring G; Giagounidis A; Büsche G; Kreipe HH; Zimmermann M; Hellström-Lindberg E; Aul C; Schlegelberger B
Ann Hematol; 2010 Apr; 89(4):365-74. PubMed ID: 19855965
[TBL] [Abstract][Full Text] [Related]
7. Extended survival and reduced risk of AML progression in erythroid-responsive lenalidomide-treated patients with lower-risk del(5q) MDS.
List AF; Bennett JM; Sekeres MA; Skikne B; Fu T; Shammo JM; Nimer SD; Knight RD; Giagounidis A;
Leukemia; 2014 May; 28(5):1033-40. PubMed ID: 24150217
[TBL] [Abstract][Full Text] [Related]
8. Clinical characteristics and outcomes according to age in lenalidomide-treated patients with RBC transfusion-dependent lower-risk MDS and del(5q).
Fenaux P; Giagounidis A; Selleslag D; Beyne-Rauzy O; Mittelman M; Muus P; Nimer SD; Hellström-Lindberg E; Powell BL; Guerci-Bresler A; Sekeres MA; Deeg HJ; Del Cañizo C; Greenberg PL; Shammo JM; Skikne B; Yu X; List AF
J Hematol Oncol; 2017 Jun; 10(1):131. PubMed ID: 28651604
[TBL] [Abstract][Full Text] [Related]
9. Multivariate time-dependent comparison of the impact of lenalidomide in lower-risk myelodysplastic syndromes with chromosome 5q deletion.
Sánchez-García J; Del Cañizo C; Lorenzo I; Nomdedeu B; Luño E; de Paz R; Xicoy B; Valcárcel D; Brunet S; Marco-Betes V; García-Pintos M; Osorio S; Tormo M; Bailén A; Cerveró C; Ramos F; Diez-Campelo M; Such E; Arrizabalaga B; Azaceta G; Bargay J; Arilla MJ; Falantes J; Serrano-López J; Sanz GF;
Br J Haematol; 2014 Jul; 166(2):189-201. PubMed ID: 24716538
[TBL] [Abstract][Full Text] [Related]
10. Randomized Phase III Study of Lenalidomide Versus Placebo in RBC Transfusion-Dependent Patients With Lower-Risk Non-del(5q) Myelodysplastic Syndromes and Ineligible for or Refractory to Erythropoiesis-Stimulating Agents.
Santini V; Almeida A; Giagounidis A; Gröpper S; Jonasova A; Vey N; Mufti GJ; Buckstein R; Mittelman M; Platzbecker U; Shpilberg O; Ram R; Del Cañizo C; Gattermann N; Ozawa K; Risueño A; MacBeth KJ; Zhong J; Séguy F; Hoenekopp A; Beach CL; Fenaux P
J Clin Oncol; 2016 Sep; 34(25):2988-96. PubMed ID: 27354480
[TBL] [Abstract][Full Text] [Related]
11. Early lenalidomide treatment for low and intermediate-1 International Prognostic Scoring System risk myelodysplastic syndromes with del(5q) before transfusion dependence.
Oliva EN; Lauseker M; Aloe Spiriti MA; Poloni A; Cortelezzi A; Palumbo GA; Balleari E; Sanpaolo G; Volpe A; Ricco A; Ronco F; Alati C; D'Errigo MG; Santacaterina I; Kündgen A; Germing U; Latagliata R
Cancer Med; 2015 Dec; 4(12):1789-97. PubMed ID: 26376955
[TBL] [Abstract][Full Text] [Related]
12. Treatment of Patients With Myelodysplastic Syndrome With Lenalidomide in Clinical Routine in Austria.
Aschauer G; Greil R; Linkesch W; Nösslinger T; Stauder R; Burgstaller S; Fiegl M; Fridrik M; Girschikofsky M; Keil F; Petzer A
Clin Lymphoma Myeloma Leuk; 2015 Nov; 15(11):e143-9. PubMed ID: 26422252
[TBL] [Abstract][Full Text] [Related]
13. Short- and long-term benefits of lenalidomide treatment in patients with lower-risk del(5q) myelodysplastic syndromes.
Komrokji RS; List AF
Ann Oncol; 2016 Jan; 27(1):62-8. PubMed ID: 26504152
[TBL] [Abstract][Full Text] [Related]
14. Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5q.
Raza A; Reeves JA; Feldman EJ; Dewald GW; Bennett JM; Deeg HJ; Dreisbach L; Schiffer CA; Stone RM; Greenberg PL; Curtin PT; Klimek VM; Shammo JM; Thomas D; Knight RD; Schmidt M; Wride K; Zeldis JB; List AF
Blood; 2008 Jan; 111(1):86-93. PubMed ID: 17893227
[TBL] [Abstract][Full Text] [Related]
15. Lenalidomide for del(5q) and non-del(5q) myelodysplastic syndromes.
Giagounidis AA
Semin Hematol; 2012 Oct; 49(4):312-22. PubMed ID: 23079061
[TBL] [Abstract][Full Text] [Related]
16. Clinical effect of increasing doses of lenalidomide in high-risk myelodysplastic syndrome and acute myeloid leukemia with chromosome 5 abnormalities.
Möllgård L; Saft L; Treppendahl MB; Dybedal I; Nørgaard JM; Astermark J; Ejerblad E; Garelius H; Dufva IH; Jansson M; Jädersten M; Kjeldsen L; Linder O; Nilsson L; Vestergaard H; Porwit A; Grønbæk K; Hellström-Lindberg E
Haematologica; 2011 Jul; 96(7):963-71. PubMed ID: 21719884
[TBL] [Abstract][Full Text] [Related]
17. Polish experience of lenalidomide in the treatment of lower risk myelodysplastic syndrome with isolated del(5q).
Butrym A; Lech-Maranda E; Patkowska E; Kumiega B; Bieniaszewska M; Mital A; Madry K; Torosian T; Wichary R; Rybka J; Warzocha K; Mazur G
BMC Cancer; 2015 Jul; 15():508. PubMed ID: 26152663
[TBL] [Abstract][Full Text] [Related]
18. Outcome of Lower-Risk Patients With Myelodysplastic Syndromes Without 5q Deletion After Failure of Erythropoiesis-Stimulating Agents.
Park S; Hamel JF; Toma A; Kelaidi C; Thépot S; Campelo MD; Santini V; Sekeres MA; Balleari E; Kaivers J; Sapena R; Götze K; Müller-Thomas C; Beyne-Rauzy O; Stamatoullas A; Kotsianidis I; Komrokji R; Steensma DP; Fensterl J; Roboz GJ; Bernal T; Ramos F; Calabuig M; Guerci-Bresler A; Bordessoule D; Cony-Makhoul P; Cheze S; Wattel E; Rose C; Vey N; Gioia D; Ferrero D; Gaidano G; Cametti G; Pane F; Sanna A; Germing U; Sanz GF; Dreyfus F; Fenaux P
J Clin Oncol; 2017 May; 35(14):1591-1597. PubMed ID: 28350519
[TBL] [Abstract][Full Text] [Related]
19. Relationship of treatment-related cytopenias and response to lenalidomide in patients with lower-risk myelodysplastic syndromes.
Sekeres MA; Maciejewski JP; Giagounidis AA; Wride K; Knight R; Raza A; List AF
J Clin Oncol; 2008 Dec; 26(36):5943-9. PubMed ID: 19018091
[TBL] [Abstract][Full Text] [Related]
20. Lenalidomide in lower-risk myelodysplastic syndromes with karyotypes other than deletion 5q and refractory to erythropoiesis-stimulating agents.
Sibon D; Cannas G; Baracco F; Prebet T; Vey N; Banos A; Besson C; Corm S; Blanc M; Slama B; Perrier H; Fenaux P; Wattel E;
Br J Haematol; 2012 Mar; 156(5):619-25. PubMed ID: 22211483
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
